Operating income before deduction of amortization: exactsciences.com (EXAS)

Volatility in actual operating profit is driven by the monopoly position of Cologuard and inelastic demand. 66.16 captures a new level while Exact Sciences (EXAS) resists the expansion of biotech startups in the liquid biopsy segment. The business's stability is supported by an impeccable medical reputation and physician trust, which smooths out the market fluctuations reflected in this chart.

Absolute operating profit reflects the real scale of the Exact Sciences business, measuring cash flow before accounting for asset depreciation. This indicator allows investors to assess the efficiency of fund generation from core operations. By analyzing the company's operating result before depreciation and amortization, one can determine the capital's margin of safety. The metric's trend reveals vulnerability to marketing costs and competition within the biopsy sector. Steady growth of this indicator confirms the resilience of the model despite its dependence on a single product.